Parkinsons Disease - Pipeline Review, H2 2020

Parkinsons Disease - Pipeline Review, H2 2020



latest Pharmaceutical and Healthcare disease pipeline guide Parkinsons Disease - Pipeline Review, H2 2020, provides an overview of the Parkinsons Disease (Central Nervous System) pipeline landscape.

Parkinsons disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Parkinsons Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Parkinsons Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Parkinsons Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinsons Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 48, 62, 4, 224, 97 and 9 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 52 and 19 molecules, respectively.

Parkinsons Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Parkinsons Disease (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Parkinsons Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Parkinsons Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Parkinsons Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Parkinsons Disease (Central Nervous System)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Parkinsons Disease (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Parkinsons Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
Introduction
Parkinsons Disease - Overview
Parkinsons Disease - Therapeutics Development
Parkinsons Disease - Therapeutics Assessment
Parkinsons Disease - Companies Involved in Therapeutics Development
Parkinsons Disease - Drug Profiles
Parkinsons Disease - Dormant Projects
Parkinsons Disease - Discontinued Products
Parkinsons Disease - Product Development Milestones
Appendix

List Of Tables

Number of Products under Development for Parkinsons Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Parkinsons Disease - Pipeline by 1st Bio Therapeutics Inc, H2 2020
Parkinsons Disease - Pipeline by 4D Pharma Plc, H2 2020
Parkinsons Disease - Pipeline by Abaxy Sprl, H2 2020
Parkinsons Disease - Pipeline by AbbVie Inc, H2 2020
Parkinsons Disease - Pipeline by Abfero Pharmaceuticals Inc, H2 2020
Parkinsons Disease - Pipeline by Abivax SA, H2 2020
Parkinsons Disease - Pipeline by ABL Bio Inc, H2 2020
Parkinsons Disease - Pipeline by AC Immune SA, H2 2020
Parkinsons Disease - Pipeline by Accure Therapeutics SL, H2 2020
Parkinsons Disease - Pipeline by Acelot Inc, H2 2020
Parkinsons Disease - Pipeline by Addex Therapeutics Ltd, H2 2020
Parkinsons Disease - Pipeline by Adicet Bio Inc, H2 2020
Parkinsons Disease - Pipeline by Affichem SA, H2 2020
Parkinsons Disease - Pipeline by AFFiRiS AG, H2 2020
Parkinsons Disease - Pipeline by Carmot Therapeutics Inc, H2 2020
Parkinsons Disease - Pipeline by Carna Biosciences Inc, H2 2020
Parkinsons Disease - Pipeline by Casma Therapeutics Inc, H2 2020
Parkinsons Disease - Pipeline by Cavion LLC, H2 2020
Parkinsons Disease - Pipeline by CavoGene LifeSciences, H2 2020
Parkinsons Disease - Pipeline by Celavie Biosciences LLC, H2 2020
Parkinsons Disease - Pipeline by CellCure, H2 2020
Parkinsons Disease - Pipeline by Cellivery Therapeutics Inc, H2 2020
Parkinsons Disease - Pipeline by Cellix Bio Pvt Ltd, H2 2020
Parkinsons Disease - Pipeline by Cerecin Inc, H2 2020
Parkinsons Disease - Pipeline by Cerecor Inc, H2 2020
Parkinsons Disease - Pipeline by CereSpir Inc, H2 2020
Parkinsons Disease - Pipeline by Cerevance Inc, H2 2020
Parkinsons Disease - Pipeline by Cerevel Therapeutics LLC, H2 2020
Parkinsons Disease - Pipeline by CHA Biotech Co Ltd, H2 2020
Parkinsons Disease - Pipeline by Chamishi Therapeutics Inc, H2 2020
Parkinsons Disease - Pipeline by Chase Therapeutics Corp, H2 2020
Parkinsons Disease - Pipeline by Chiesi Farmaceutici SpA, H2 2020
Parkinsons Disease - Pipeline by CholesteniX Ltd, H2 2020
Parkinsons Disease - Pipeline by Chongqing Pharmaceutical Research Institute Co Ltd, H2 2020
Parkinsons Disease - Pipeline by Ci Therapeutics, H2 2020
Parkinsons Disease - Pipeline by Clayton Biotechnologies Inc, H2 2020
Parkinsons Disease - Pipeline by Clene Nanomedicine Inc, H2 2020
Parkinsons Disease - Pipeline by Clevexel Pharma SA, H2 2020
Parkinsons Disease - Pipeline by InnoMedica Holding AG, H2 2020
Parkinsons Disease - Pipeline by Intec Pharma Ltd, H2 2020
Parkinsons Disease - Pipeline by International Stem Cell Corp, H2 2020
Parkinsons Disease - Pipeline by Intra-Cellular Therapies Inc, H2 2020
Parkinsons Disease - Pipeline by Invisio Ltd, H2 2020
Parkinsons Disease - Pipeline by Io Therapeutics Inc, H2 2020
Parkinsons Disease - Pipeline by Ionis Pharmaceuticals Inc, H2 2020
Parkinsons Disease - Pipeline by IRLAB Therapeutics AB, H2 2020
Parkinsons Disease - Pipeline by Jazz Pharmaceuticals Plc, H2 2020
Parkinsons Disease - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2020
Parkinsons Disease - Pipeline by Junaxo Inc, H2 2020
Parkinsons Disease - Pipeline by Kainos Medicine Inc, H2 2020
Parkinsons Disease - Pipeline by Kariya Pharmaceuticals IVS, H2 2020
Parkinsons Disease - Dormant Projects, H2 2020
Parkinsons Disease - Discontinued Products, H2 2020

List Of Figures

Number of Products under Development for Parkinsons Disease, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020

Fill The Form For Sample Request

There is no Reviews available